People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology, Other Energy
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evofem Biosciences, Inc. | — | Biotechnology | Series B | $133.6M | $4.3M | 2019 |
| Verenium Corp | — | Other Energy | Series A | $33.8M | $77.3M | 2012 |
Alexander A. Fitzpatrick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alexander A. Fitzpatrick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Johnson | 1 | 11 |
| Thomas Lynch | 1 | 7 |
| Joshua Ruch | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| William Hall | 1 | 5 |
| Jeffrey G. Black | 1 | 3 |
| Thomas F. Darden II | 1 | 3 |
| Jenny Yip | 1 | 3 |
| Michael Zak | 1 | 2 |
| Kim P. Kamdar | 1 | 2 |
| John F. Dee | 1 | 2 |
| Simon Best | 1 | 2 |
| Natalie Douglas | 1 | 2 |
| Joshua F. Ruch | 1 | 2 |
| William H. Baum | 1 | 2 |
| Gerald M Haines | 1 | 2 |
| James H. Cavanaugh | 1 | 2 |
| Ellen Thomas | 1 | 1 |
| Colin Rutherford | 1 | 1 |
| Kelly Culwell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.